{"title":"The effect of serial dilution of betamethasone-17-valerate on blanching potential and chemical stability.","authors":"K S Ryatt, J A Cotterill, A Mehta","doi":"10.1111/j.1365-2710.1983.tb01044.x","DOIUrl":"https://doi.org/10.1111/j.1365-2710.1983.tb01044.x","url":null,"abstract":"<p><p>The effect of serial dilution of betamethasone-17-valerate (Betnovate ointment) in Unguentum Merck was investigated using a single application blanching assay in 10 subjects and high performance liquid chromatography. There was no statistically significant difference between any of the diluted formulations with regard to blanching potential. Chemical stability was maintained following a 1:32 dilution for 2 months and 1:4 dilution for 5 months at least, after storage at room temperature.</p>","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"143-5"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2710.1983.tb01044.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17925726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The use of buccal partitioning as a model of drug absorption interactions.","authors":"J C McElnay, C Mooney","doi":"10.1111/j.1365-2710.1983.tb01043.x","DOIUrl":"https://doi.org/10.1111/j.1365-2710.1983.tb01043.x","url":null,"abstract":"<p><p>Bioavailability describes both the rate and extent of drug absorption. The buccal absorption technique is a useful method for the examination of changed extent of drug absorption resulting from drug absorption interactions. The present work examined the usefulness of drug recovery profiles (after buccal absorption) in evaluating the rate of drug absorption. Recovery data, in the case of propranolol, did not change markedly after marked changes in the drug absorption rate, indicating that recovery profiles are a poor monitoring tool for changed absorption rates. The rate of drug absorption can be found using the buccal absorption method; however, this involves several different experiments on different days and, also, data must be found by measuring the drug in the absorption solution which also contains the interactant. The latter agent may interfere with drug assay procedures. The present work involved the model drug propranolol. Other drugs perhaps may behave differently.</p>","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"137-42"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2710.1983.tb01043.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17925725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A community pharmacy-based survey of antihypertensive and antidiabetic drug dosages in Northern Ireland.","authors":"K Griffiths, D G McDevitt","doi":"10.1111/j.1365-2710.1983.tb01040.x","DOIUrl":"https://doi.org/10.1111/j.1365-2710.1983.tb01040.x","url":null,"abstract":"International drug utilization data comparisons for antihypertensive and anti‐diabetic agents based on standard daily dosage units, Defined Daily Doses (DDD), show that less of these drugs are prescribed per head of population in Northern Ireland than in Norway or Sweden. A study was designed to investigate whether actual prescribing practices in Northern Ireland might account for some of these apparent differences by comparing the average prescribed daily dose, (PDD) with the DDD for antihypertensive and antidiabetic drugs.","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"115-24"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2710.1983.tb01040.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17201728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Plasma xanthine levels in premature infants treated for apnoea with theophylline.","authors":"D B Hargreaves, G T Lealman, B A Mulley","doi":"10.1111/j.1365-2710.1983.tb01042.x","DOIUrl":"https://doi.org/10.1111/j.1365-2710.1983.tb01042.x","url":null,"abstract":"<p><p>Evidence is presented that oral theophylline doses of 3 mg per kg per 24 h in premature babies produces plasma levels of theophylline and caffeine of about 5 and 1-2 mg/l respectively in most subjects.</p>","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"133-6"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2710.1983.tb01042.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17925724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"What are the mechanisms by which pro-drugs are activated in the body?","authors":"H Bundgaard","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"153-4"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17925727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Microcomputer organization of parenteral nutrition in the neonate.","authors":"N McLellan","doi":"10.1111/j.1365-2710.1983.tb01045.x","DOIUrl":"https://doi.org/10.1111/j.1365-2710.1983.tb01045.x","url":null,"abstract":"<p><p>The use of a microcomputer is described to simplify the organization of neonatal parenteral feeding and extend the flexibility of the technique, providing a hard copy prescription and regime analysis for each patient. Its use can save medical and pharmacy time and conserve expensive reagents. The programme is readily adaptable to different feeding policies and the system is simple, works well in practice and is cheap to run.</p>","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"147-51"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2710.1983.tb01045.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17468848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers.","authors":"A W Harcus, A E Ward, S I Ankier, G R Kimber","doi":"10.1111/j.1365-2710.1983.tb01041.x","DOIUrl":"https://doi.org/10.1111/j.1365-2710.1983.tb01041.x","url":null,"abstract":"<p><p>The pharmacokinetic parameters of Molipaxin capsules and a trazodone liquid formulation have been compared in healthy volunteers. The mean area under the plasma concentration/time curve was 10.07 micrograms h ml-1 and 10.44 micrograms h ml-1, for Molipaxin capsules and trazodone liquid, respectively. The difference was not statistically significant. There was considerable individual variation between the observed maximum plasma concentration of Molipaxin capsules and trazodone liquid but the mean values of 1.61 micrograms/ml and 1.66 micrograms/ml, respectively, were very similar. The time to observed maximum plasma concentrations varied from 15 min to 4 h, but there was no statistical difference between the two formulations. The terminal phase half-life was 7.16 h for Molipaxin capsules and 6.73 h for trazodone liquid. The difference was not statistically significant. Molipaxin capsules and trazodone liquid have similar kinetic profiles and they are considered to have comparable bioavailability. Tolerance to the two formulations was similar.</p>","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"125-32"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2710.1983.tb01041.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17742895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The clinical pharmacology of acyclovir.","authors":"H J Rogers, A S Fowle","doi":"10.1111/j.1365-2710.1983.tb01038.x","DOIUrl":"https://doi.org/10.1111/j.1365-2710.1983.tb01038.x","url":null,"abstract":"29. 49. Mindcl, A., Adlcr, M.W., Suthcrland, S. & Fiddian, A.P. (1982) Intravenous acyclovir treatment for primary genital herpes. Lancet, i, 697-700. 50. Pctcrslund, N.A., Scycr-Hanscn, K., Ipscn, J., Esmann, V., Schonhcydcr, H. & Juhl, H. (1981) Acyclovir in herpes zoster. Lancet, ii, 827-883. 51. Jucl-Jcnscn, B.E., Khan, J. & Pasvol, G . (1982) High-dose acyclovir in the treatment of zoster. A double blind controlled uial. VIII International Congress of Infectious and Parasuic Lhscarrr, Stockholm, Sweden, 7-1 f June 1982, Abstract 13.7. 52. Bean, B., Braun, C. & Balfour, H.H. (1982) Acyclovir therapy for acute herpes zoster. Lancet, ii, I 1%","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 2","pages":"89-102"},"PeriodicalIF":0.0,"publicationDate":"1983-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2710.1983.tb01038.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17407858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapeutic progress--review VII. The medical treatment of Paget's disease.","authors":"M C Sheppard","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The presentation of Paget's disease varies from a painful or deforming skeletal affliction to an asymptomatic disorder diagnosed on routine biochemical or radiological assessment. When involvement of the peripheral skeleton by Paget's disease is extensive, the clinical diagnosis is usually clear. Affected bones are thickened and deformed and the overlying skin is warm. Bone pain is sometimes severe and malignant change rarely occurs. The new bone formed is structurally abnormal and is consequently liable to deformity and fractures. Serum alkaline phosphatase concentrations and urinary hydroxyproline excretion are raised. Characteristic X-ray changes are seen. Paget's disease should be treated when it causes skeletal pain and tenderness, or when there are neurological symptoms, fractures, marked deformities, or other complications. New therapeutic agents offer both symptomatic relief and some control of the basic disease process. Simple analgesics should be tried before proceeding to the anti-osteoclastic agents, calcitonin, diphosphonates and mithramycin. All are effective in relieving bone pain and improving biochemical indices. The major advantage of the diphosphonates lies in their oral usage and thus, the number of patients who nowadays require calcitonin is small. The majority of patients should be commenced on a course of diphosphonate therapy (EHDP in most instances), but if clinical response is unsatisfactory calcitonin should be tried. Mithramycin should be reserved for special indications e.g. an elderly patient with severe disabling pain.</p>","PeriodicalId":77862,"journal":{"name":"Journal of clinical and hospital pharmacy","volume":"8 1","pages":"35-44"},"PeriodicalIF":0.0,"publicationDate":"1983-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17285524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}